Drug treatment of Parkinson's disease.

PubWeight™: 1.19‹?› | Rank: Top 10%

🔗 View Article (PMC 2548944)

Published in BMJ on March 04, 1995

Authors

N Quinn1

Author Affiliations

1: Institute of Neurology, National Hospital for Neurology and Neurosurgery, London.

Articles cited by this

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med (1984) 2.71

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54

Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology (1993) 2.16

Young onset Parkinson's disease. Mov Disord (1987) 1.67

Neurosurgical horizons in Parkinson's disease. Neurology (1993) 1.62

Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol (1978) 1.58

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology (1989) 1.55

Clozapine in the treatment of psychosis in Parkinson's disease. Neurology (1989) 1.45

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology (1991) 1.41

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 1.30

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord (1993) 1.30

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology (1987) 1.17

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol (1990) 1.13

Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med (1987) 1.03

The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology (1993) 0.98

Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol (1988) 0.98

Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol (1987) 0.96

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 0.91

Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology (1988) 0.90

The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry (1989) 0.89

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry (1994) 0.87

Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand (1990) 0.85

Drug treatment of Parkinson's disease: is "polypharmacy" best? J Neurol Neurosurg Psychiatry (1994) 0.80

Articles by these authors

Parkinsonism--recognition and differential diagnosis. BMJ (1995) 1.45